25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.
4 citations
,
May 2025 in “Frontiers in Immunology” This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.
127 citations
,
January 2000 in “Journal of Investigative Dermatology” This study found that pro-inflammatory cytokines and apoptotic mechanisms, specifically involving granzyme B and Fas pathways, are associated with chronic alopecia areata, indicating their potential role in the disease's persistence.
5 citations
,
March 2025 in “Pediatric Dermatology” This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.
45 citations
,
May 2024 in “International Journal of Molecular Sciences” This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.